Epilepsy is one of the most common neurological diseases globally and it is characterised by what are known as “epileptic seizures”. These seizures are sudden and brief episodes caused by abnormal neuron activity and occur with signs or symptoms that vary from person to person. It is usually impossible to predict when a seizure will occur.
Although many drug therapies exist, between 20 and 30% of patients do not respond adequately to treatment: this condition is known as drug-resistant epilepsy. It is a form of epilepsy that both patients and doctors find extremely complex to manage, but the latest research seems to pave the way for innovative therapies.
In this article, we will look at what drug resistance means, the causes of this medical condition and the latest developments in research focused on affected patients, including the youngest.
Drug-resistant epilepsy (DRE) occurs when a patient fails to remain seizure-free when treated with at least two or more anti-epileptic drugs used alone or in combination, at the highest possible dose.
According to the guidelines, the time needed to determine whether epilepsy is drug-resistant varies according to the frequency of seizures, but in cases where seizures are very frequent, observation should not be extended beyond 3-4 years, nor should more than 3-5 treatment regimens be attempted. Some experts suggest that one year is enough, as the probability of success drops dramatically after the first and second drug fail to be effective. A British study (Kwan and Brodie, N. Eng.J.Med – 342: 3149, 2000) confirms that the first drug is successful in 47% of cases, the second in 13%, the third in only 1%, while a combination of two drugs works in 3% of cases. This obviously makes it difficult to control epileptic seizures, which continue to occur.
The condition affects both adults and children and, of course, increases the difficulties that patients face on a daily basis, such as, for example, the problems of polypharmacy in epilepsy or the comorbidities of children suffering from epilepsy, which further complicate therapeutic management.
Sometimes, however, it is a case of false or pseudo-drug resistance. This happens when epilepsy is misdiagnosed and therefore the prescribed medication or its dosage is not adequate, or when the diagnosis is not accurate in terms of syndrome. There are additional factors that can affect the success of medicines, such as poor patient compliance with the treatment.
The causes of drug-resistant epilepsy are multiple and complex. In some cases, resistance to drugs may depend on the type of epilepsy or where the seizures occur in the brain. Other possible causes include:
Astrocytes are glial cells in the central nervous system that play an essential role in the proper functioning of neurons. In addition to providing structural support to neurons, astrocytes also regulate ion balance and release molecules that can influence neuron excitability. When these control mechanisms are altered, as occurs in some epilepsy patients, astrocytes can contribute to seizure generation and drug resistance.
Studies on drug-resistant epilepsy have led to the development of new treatments for epileptic seizures aimed at improving the course of the disease, experimentally in particular. Some of these therapies specifically aim to correct astrocyte dysfunction. These medicines must be able to cross the blood-brain barrier, but with minimal side effects. New medical developments include:
Let’s take a look together at the main therapies for drug-resistant epilepsy.
As we hinted earlier, in recent years, medical research has made significant progress in the treatment of drug-resistant epilepsy. While still a complex challenge, some new therapies have been developed that offer hope to patients.
It has been shown that the integration of Vitamin B6 can be a valid solution for drug-resistant epilepsy in children, especially in epilepsy linked to pyridoxine dependence, which is caused by rare autosomal recessive genetic disorders.
There are also auxiliary treatments such as Epilamba, the innovative supplement for childhood epilepsy comorbidities developed by Cor.Con. International: its formulation provides valuable support to alleviate the side effects of medicines in paediatric patients without adding more medicines to drug-rich therapies. This is crucial in complex contexts such as these, because it helps to improve both the quality of life of young patients and their compliance with treatment.
While drug-resistant epilepsy remains a complex challenge for medicine, advances in treatment and research – including in the area of food supplements – mean new opportunities are opening up to improve the lives of people living with this condition.